REDWOOD CITY, Calif., June  01, 2026  (GLOBE NEWSWIRE) --  Exicure, Inc. (NASDAQ:XCUR, the &#34;Company&#34;)) announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock

XCUR

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

Exicure regains Nasdaq compliance after Q1 2026 filing delay

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>REDWOOD CITY, Calif., June  01, 2026  (GLOBE NEWSWIRE) --  Exicure, Inc. (NASDAQ:XCUR, the &amp;#34;Company&amp;#34;)) announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Exicure disclosed Nasdaq notified it of non-compliance due to a delayed Q1 2026 Form 10-Q, and that it filed the report on May 29 and believes it has regained compliance. The delay was tied to changes in finance personnel; the company is pursuing strategic alternatives after restructuring and pausing clinical activities, with a lead stem cell mobilization program under evaluation.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Nasdaq notified Exicure of late Q1 2026 Form 10-Q filing on May 28.</li><li>Exicure filed the 10-Q on May 29 and says it regained compliance.</li><li>Restructuring paused clinical activities; company exploring strategic alternatives.</li><li>Lead program targets stem cell mobilization in multiple myeloma and SCD.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Exicure, Inc. (XCUR)</strong>: Regulatory/compliance development and strategic-review backdrop; potential valuation implications.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The release centers on Nasdaq compliance and ongoing strategic-reorientation, both of which can influence execution risk and stock valuation.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Regained Nasdaq compliance could reduce liquidity risk and stabilize price.</li><li>Strategic-alternatives process may trigger deal-related volatility.</li><li>Lead stem cell mobilization program remains a key value driver.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Nasdaq Listing Rule 5250(c)(1) non-compliance cited for Q1 2026 Form 10-Q.</li><li>Delay due to changes in financial reporting personnel.</li><li>10-Q filed: May 29, 2026.</li><li>Nasdaq notification: May 28, 2026.</li><li>Exicure acquired a clinical-stage hematologic-disease company in Jan 2025.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Regulatory risk abates in the near term; monitor strategic-alternative progress over 6–12 months for XCUR.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">REDWOOD CITY, Calif., June  01, 2026  (GLOBE NEWSWIRE) -- <strong> Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/XCUR">XCUR</a>, the "Company")) </strong>announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on May 28, 2026 indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2026.</p>  <p align="justify">The delay was primarily due to additional time required following changes in the Company's financial reporting personnel and related filing procedures.</p>  <p align="justify">The Company filed its Quarterly Report on Form 10-Q for the three months ended March 31, 2026 with the Securities and Exchange Commission on May 29, 2026 and believes that it has regained compliance with Nasdaq Listing Rule 5250(c)(1).</p>  <p align="justify"><strong>About Exicure, Inc.</strong></p>  <p align="justify">Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/XCUR">XCUR</a>) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value. In January 2025, it acquired a clinical-stage biotechnology company developing therapeutics for hematologic diseases. The Company's lead program in development is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. For more information, visit <a href="http://www.exicuretx.com" title="www.exicuretx.com">www.exicuretx.com</a>.</p>  <p align="justify"><strong>Cautionary Note Regarding Forward Looking Statements</strong></p>  <p align="justify">Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, statements related to the Company's review and analysis in connection with the Form 10-Q and the Company's expectations with respect to its financial results for the three months ended March 31, 2026 and the definitive filing date of the Form 10-Q. Forward-looking statements are based on management's current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. For a discussion of risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 25, 2026, as updated by the Company's subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information or to publicly announce the results of any revisions to any of such statements to reflect future events or developments, except as required by law.</p>  <p><strong>Media Contact:</strong></p>  <p>Exicure, Inc.</p>  <p><a href="mailto:pr@exicuretx.com">pr@exicuretx.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcyOTk3NSM3NjMxMTk4IzIwMjAyMzU="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/YjUxMTdhYjgtOWY3Yy00YmQzLTg0ZjctNzY3ZmRiYWJiYjllLTEwMzE4MDctMjAyNi0wNi0wMS1lbg==/tiny/Exicure-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/3a5f958d-422c-4a97-a96d-cf06f640b587"><img src="https://ml.globenewswire.com/media/3a5f958d-422c-4a97-a96d-cf06f640b587/small/exicure-logo-final-full-color-072515-png.png" border="0" width="150" height="37" alt="Primary Logo"></img></a></p>

Exicure disclosed Nasdaq notified it of non-compliance due to a delayed Q1 2026 Form 10-Q, and that it filed the report on May 29 and believes it has regained compliance. The delay was tied to changes in finance personnel; the company is pursuing strategic alternatives after restructuring and pausing clinical activities, with a lead stem cell mobilization program under evaluation.

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News